Delgocitinib has not yet received FDA approval for any indication [1].
What is Delgocitinib?
Delgocitinib is an investigational Janus kinase (JAK) inhibitor [1]. It is being developed for the treatment of inflammatory conditions, including atopic dermatitis and alopecia areata [1].
What stage of development is Delgocitinib in?
Delgocitinib has been investigated in Phase 3 clinical trials for atopic dermatitis [1]. These trials have explored its efficacy and safety in adult patients with moderate to severe disease [1].
When might Delgocitinib be approved?
The timeline for potential FDA approval of delgocitinib depends on ongoing clinical trials and the subsequent submission of a New Drug Application (NDA) to the agency [1]. As of current information, no specific approval date has been announced.
How does Delgocitinib work?
Delgocitinib works by inhibiting JAK enzymes, which play a role in signaling pathways that drive inflammation [1]. By blocking these pathways, the drug aims to reduce the inflammatory response associated with certain skin conditions.
What are the potential side effects of Delgocitinib?
Based on clinical trial data, common side effects observed with delgocitinib include nasopharyngitis, acne, and upper respiratory tract infections [1]. Serious side effects observed in clinical trials have included infections and potential cardiovascular events, although further data is needed to fully characterize the risk profile [1].
What other JAK inhibitors are approved for skin conditions?
Several other JAK inhibitors are currently FDA-approved for dermatological conditions. These include ruxolitinib, upadacitinib, and abrocitinib, which are indicated for atopic dermatitis [2]. Tofacitinib is approved for moderate to severe chronic plaque psoriasis and psoriatic arthritis [2].
What is the status of Delgocitinib in other countries?
Delgocitinib has been approved in Japan for atopic dermatitis under the brand name Corectim [1].
Sources:
[1] DrugPatentWatch.com
[2] https://www.drugpatentwatch.com/